TBCRC 008: Early Change in (18)F-FDG Uptake on PET Predicts Response to Preoperative Systemic Therapy in Human Epidermal Growth Factor Receptor 2–Negative Primary Operable Breast Cancer

Epigenetic modifiers, including the histone deacetylase inhibitor vorinostat, may sensitize tumors to chemotherapy and enhance outcomes. We conducted a multicenter randomized phase II neo-adjuvant trial of carboplatin and nanoparticle albumin-bound paclitaxel (CP) with vorinostat or placebo in women...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Nucl Med
Main Authors: Connolly, Roisin M., Leal, Jeffrey P., Goetz, Matthew P., Zhang, Zhe, Zhou, Xian C., Jacobs, Lisa K., Mhlanga, Joyce, Joo, H O, Carpenter, John, Storniolo, Anna Maria, Watkins, Stanley, Fetting, John H., Miller, Robert S., Sideras, Kostandinos, Jeter, Stacie C., Walsh, Bridget, Powers, Penny, Zorzi, Jane, Boughey, Judy C., Davidson, Nancy E., Carey, Lisa A., Wolff, Antonio C., Khouri, Nagi, Gabrielson, Edward, Wahl, Richard L., Stearns, Vered
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4352313/
https://ncbi.nlm.nih.gov/pubmed/25476537
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2967/jnumed.114.144741
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados